As a pain physician, I see patients every week whose lives have been quietly hijacked by neuropathy. They describe burning feet that keep them awake at night, the strange “electric” jolts that shoot up their legs, or the numbness that makes them fear falling. Many have diabetes. Many have already tried multiple medications. And too many have been told, “There’s nothing more we can do.”
That is simply not true.
Neuropathy is not a single disease; it is damage to the peripheral nerves, the intricate wiring that carries signals between your brain, spinal cord, and the rest of your body. When those wires are frayed or short-circuit, the messages become garbled (pain where there should be none, numbness where there should be feeling, or loss of control over automatic functions like heart rate, digestion, or sweating). This damage disrupts communication between the central nervous system and the rest of the body, producing sensory symptoms (numbness, tingling, burning, or pain), motor symptoms (weakness or loss of coordination), autonomic symptoms (problems with heart rate, blood pressure, digestion, sweating, or sexual function), or combinations of these.
The simple story of why nerves fail (especially in diabetes)
Picture your longest nerves as they travel all the way to your toes and as delicate power lines stretching for miles. In diabetes, high blood sugar acts like corrosive weather that slowly eats away at those lines. Excess glucose creates sticky “advanced glycation end-products” that gum up proteins inside the nerve. It also floods the nerve cells with toxic by-products, generates damaging free radicals (oxidative stress), and starves the tiny blood vessels that nourish the nerves. The result is a length-dependent “dying-back” process: the farthest ends of the nerves wither first, producing the classic stocking-and-glove pattern.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Interesting twist: The pain itself is not just from the damaged nerve. The spinal cord and brain begin to amplify the faulty signals, which is a process called central sensitization. That is why some people feel excruciating pain even when the original nerve injury is modest. Understanding this dual peripheral-and-central story is what allows us to treat neuropathy more effectively today.
The main types of neuropathies include:
- Distal symmetric polyneuropathy (the most common form, especially in diabetes) starts in the feet and hands.
- Autonomic neuropathy: Affects heart rate, blood pressure, digestion, bladder, and sexual function.
- Proximal neuropathy (diabetic amyotrophy): Sudden pain and weakness in the thighs or hips.
- Focal neuropathies: Single-nerve problems such as carpal tunnel or cranial-nerve palsies.
Diabetic neuropathy is the single largest cause of peripheral neuropathy in the developed world and can affect up to half of people living with diabetes over a lifetime. The good news is that strict blood-sugar control slows progression, and modern pain treatments can dramatically improve quality of life even when the underlying nerve damage cannot be fully reversed.
Evidence-based, state-of-the-art treatment options
I practice a stepwise, multimodal approach grounded in the strongest available evidence and guidelines from the American Diabetes Association and recent high-quality meta-analyses.
1. Foundational care
Optimize glucose, blood pressure, lipids, and lifestyle. Protect the feet. Address vitamin deficiencies, thyroid disease, or other reversible causes.
2. First-line neuromodulating medications (strong recommendation)
- Gabapentinoids (gabapentin, pregabalin) modulate calcium channels in the spinal cord.
- SNRIs (duloxetine is FDA-approved for painful diabetic neuropathy; venlafaxine is also effective).
- Tricyclic antidepressants (amitriptyline or nortriptyline at low nighttime doses).
Recent meta-analyses show numbers needed to treat in the range of 4-9, meaning these drugs help a meaningful portion of patients achieve clinically important pain reduction. We choose based on comorbidities (sleep, mood, kidney function, fall risk) and start low, go slow.
3. Second-line and topical therapies
High-concentration 8 percent capsaicin patches (FDA-approved for diabetic neuropathy), lidocaine 5 percent patches, and, in selected cases, botulinum toxin A injections. These can be especially useful for localized pain or when systemic side effects are a concern.
4. Advanced procedural and neuromodulation therapies
When medications fall short, we move to interventional options. For refractory painful diabetic neuropathy of the lower limbs, spinal cord stimulation (SCS) has become a true game changer.
Multiple randomized controlled trials and meta-analyses, including data through 2025-2026, demonstrate that both conventional and high-frequency (10 kHz), as well as closed-loop SCS, produce substantial, sustained pain relief, often with ≥50 percent reduction in a far higher proportion of patients than best medical therapy alone, along with improvements in quality of life and function. High-frequency SCS is typically paresthesia-free, which many patients prefer. The FDA has approved specific SCS systems for chronic intractable lower-limb pain associated with diabetic peripheral neuropathy. Some observational data suggest possible improvements in nerve conduction and a reduced risk of certain complications, though larger long-term studies are ongoing.
Other state-of-the-art tools in the pain physician’s toolkit include dorsal root ganglion stimulation for more focal pain, peripheral nerve stimulation, and carefully selected neurolytic or ablative procedures when appropriate. Every patient first undergoes a temporary trial, so we can confirm benefit before permanent implantation.
A message of realistic hope
Complete pain elimination is uncommon, but meaningful improvement with better sleep, more walking, fewer pills, and restored confidence is very achievable for most people when we use the full range of evidence-based options. Neuropathy is no longer a diagnosis that ends the conversation; it is the beginning of a tailored treatment plan.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
